Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

rVA576

6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.

OTHER

Standard of care (SOC)

6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.

Trial Locations (3)

050006

Almaty City Hospital No.7, Almaty

LT-08661

Vilnius University Hospital Santaros Klinikos , Santariškių St. 2, LT-08661,, Vilnius

Ragama/11010

University of Kelaniya, Faculty of Medicine, Thalagolla Road, Colombo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AKARI Therapeutics

INDUSTRY